New antiarrhythmic agents for atrial fibrillation and atrial flutter

Bibliography

• BENJAMIN E, LEVY D, VAZIRI S, D'AGOSTINO R, BELANGER A, WOLF P: Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA (1994) 271:840–844.
   PubMed Web of Science ®Google Scholar
• BENJAMIN E, WOLF P, D'AGOSTINO R, SILBERSHATZ H, KANEL W, LEVY D: Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation (1998) 98(10946–952.
   Google Scholar
• WOLF PA, MITCHELL JB, BAKER CS, KANNEL WB, D'AGOSTINO RB: Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch. Intern. Med. (1998) 158:229–234.
   PubMed Web of Science ®Google Scholar
• PEDERSEN O, BAGGER H, KOBER L, TORP-PEDERSEN C: The occurrence and prognostic significance of atrial fibrillation/-flutter following acute myocardial infarction. TRACE Study group. TRAndolapril Cardiac Evalution. Eur. Heart J. (1999) 20:748–754.
   PubMed Web of Science ®Google Scholar
• MIDDLEKAUF H, STEVENSON W, STEVENSON L: Prognostic significance of atrial fibrillation in advanced heart failure. A study of 390 patients. Circulation (1991) 84:40–48.
   PubMed Web of Science ®Google Scholar
• CARSON P, JOHNSON G, DUNKMAN W, FLETCHER R, FARRELL L, COHN J: The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. The V-HeFT VA Cooperative Studies Group. Circulation (1993) 87:VI102–V1110.
   Google Scholar
• KOPECKY S, GERSH B, McGOON M et al.: Lone atrial fibrillation in elderly persons. Arch. Intern. Med. (1999) 159:1118–1122.
   PubMed Web of Science ®Google Scholar
• CHEN S, CHEN Y, YEH H, TAI C, CHEN Y, LIN C: Pathophysiology of the pulmonary vein as an atrial fibrillation initiator. Pace (2003) 26:1576–1582.
   Google Scholar
• WIJEFELS M, KIRCHHOF C, DORLAND R, ALLESSIE M. Atrial fibrillation begets atrial fibrillation: a study in awake chronically instrumented goats. Circulation (1995) 92(7):1954–1968.
   PubMed Web of Science ®Google Scholar
• LID, SHINIGAWA K, PANG L et al.: Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation (2001) 104:2608–2614.
   PubMed Web of Science ®Google Scholar
• FUSTER M, RYDEN L, ASINGER RW et al.: ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. J. Am. Coll. CardioL (2001) 38:1266–1261.
   Web of Science ®Google Scholar
• WYSE D, WALDO A, DIMARCO J et al.: A comparison of rate control and rhythm control in patients with atrial fibrillation. N EngL J. Med. (2002) 347:1825–1833.
   PubMed Web of Science ®Google Scholar
• VAN GELDER I, HAGENS V, BOSKER HA et al.: A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N EngL J. Med. (2002) 347:1834–1840.
   PubMed Web of Science ®Google Scholar
• Cl-TANNER K: Current management ofsymptomatic atrial fibrillation. Drugs (2001) 61:1424–1437.
   Google Scholar
• NACCARELLI G, DORIAN P, HOHNLOSER S, COUMEL P: Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. Am. J. Cardiology (1996) 77:53A–59A.
   Google Scholar
• HOHNLOSER S, VAN DE LOO A, BAEDEKER F: Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: prospective comparison of sotalol versus quinidine. J. Am. Coll. Cardiol. (1995) 26:852–858.
   PubMed Web of Science ®Google Scholar
• CAPUCCI A, LENZI T, BORIANI G et al.: Effectiveness of loading oral flecainide for onverting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. Am. J. Cardiology (1992) 70:69–72.
   PubMed Web of Science ®Google Scholar
• DONOVAN K, POWER B, HOCKINGS B, DOBB G, LEE K-Y: Intravenous flecainide versus amiodarone for recent-onset atrial fibrillation. Am. J. Cardiology (1995) 75:693–697.
   PubMed Web of Science ®Google Scholar
• DONOVAN K, DOBB G, COOMBS L et al.: Reversion of recent-onset atrial fibrillation to sinus rhythm by intravenous flecainide. Am. J. Cardiology (1991) 67:137–141.
   PubMed Web of Science ®Google Scholar
• BERTINI G, CONTI A, FRADELLA G et al.: Propafenone versus amiodarone in field treatment of primary atrial tachydysrhythmias. j Emerg. Med. (1990) 8:15–20.
   Google Scholar
• BOTTO G, CAPUCCI A, BONINI W et al.: Conversion of recent onset atrial fibrillation to sinus rhythm using a single oral dose of propafenone: comparison of two regimens. Int. J. CardioL (1997) 58:55–61.
   PubMed Web of Science ®Google Scholar
• BORIANI G, CAPUCCI A, LENZI T, SANGUINETTI M, MAGNANI B: Propafenone for conversion of recent-onset atrial fibrillation. Chest (1995) 108:355–358.
   PubMed Web of Science ®Google Scholar
• STROOBANDT R, STIELS B, HOEBRECHTS R: Propafenone for conversion and prophylaxis of atrial fibrillation. Am. J. Cardiology (1997) 79:418–423.
   PubMed Web of Science ®Google Scholar
• Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl. J. Med. (1989) 321(6):405–412.
   Google Scholar
• Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. The Cardiac Arrhythmia Suppression Trial II Investigators. N EngL J. Med. (1992) 327:227–233.
   PubMed Web of Science ®Google Scholar
• ROY D, TALAJIC M, DORIAN P et al: Amiodarone to prevent recurrence of atrial fibrillation. N EngL J. Med. (2000) 342:913–920.
   PubMed Web of Science ®Google Scholar
• CHUN S, SAGER P, STEVENSON W, NADEMANEE K, MIDDLEKAUF H, SINGH B: Long-term efficacy of amiodarione for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. Am. J. Cardiology (1995) 76:47–50.
   PubMed Web of Science ®Google Scholar
• KOCHIADAKIS G, IGOUMENIDIS N, MARKETOU M, KALEBOUBAS M, SIMATIRAKIS E, VARDAS P: Low dose amiodarone and sotalol in the treatment of recurrent, symptomatic atrial fibrillation: a comparative, placebo controlled study. Heart (2000) 84:251–257.
   PubMed Web of Science ®Google Scholar
• VAN NOORD T, VAN GELDER I, SCHOONDERWOERD B, CRIJNS J: Immediate reinitiation of atrial fibrillation after electrical cardioversion predicts subsequent pharmacologic and electrical conversion to sinus rhythm on amiodarone. Am. J. Cardiology (2000) 86:1384–1385.
   PubMed Web of Science ®Google Scholar
• TIELEMAN R, GOSSELINK A, CRIJNS H et al.: Efficacy, safety, and determinants of conversion of atrial fibrillation and flutter with oral amiodarone. Am. J. Cardiology (1997) 79:53–57.
   PubMed Web of Science ®Google Scholar
• NOC M, STAJER D, HORVAT M: Intravenous amiodarone versus verapamil for acute conversion of paroxysmal atrial fibrillation to sinus rhythm. Am. J. Cardiology (1990) 65:679–680.
   PubMed Web of Science ®Google Scholar
• PEUHKURINEN K, NIEMELA M, YLITALO A, LINNALUOTO M, LILJA M, JUVONEN J: Effectiveness of amiodaroneas a single oral dose for recent-onset atrial fibrillation. Am. J. Cardiology (2000) 85:462–465.
   PubMed Web of Science ®Google Scholar
• CLEMO H, WOOD M, GILLIGAN D, ELLENBOGEN K: Intravenous amiodarone for acute heart rate control in the critically ill patient with atrial tachyarrhythmias. Am. J. Cardiology (1998) 81:594–598.
   PubMed Web of Science ®Google Scholar
• DEEDWANIA P, SINGH B, ELLENBOGEN K, FISHERS, FLETCHER R, SINGH S: Spontaneous conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation. Circulation (1998) 98:2574–2579.
   PubMed Web of Science ®Google Scholar
• SINGH S, FLETCHER R, FISHERS et al.: Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N EngL J. Med. (1995) 333:77–82.
   PubMed Web of Science ®Google Scholar
• VORPERIAN V, HAVIGHURST T, MILLERS, JANUARY C: Adverse effects of low dose amiodarone: a meta-analysis. J. Am. Coll. CardioL (1997) 30:791–798.
   PubMed Web of Science ®Google Scholar
• ELMING H, BRENDORP B, PEDERSEN O, KOBER L, TORP-PEDERSEN C: Dofetilide: a new drug to control cardiac arrhythmia. Expert Opin. Pharmacother. (2003) 4(0:973–985.
   PubMed Web of Science ®Google Scholar
• MOUNSEY J, DIMARCO J: Dofetilide. Circulation (2000) 102:2665–2670.
   PubMed Web of Science ®Google Scholar
• SINGH S, ZOBLE R, YELLEN L et al: Efficacy and safety dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or flutter. Circulation (2000) 102:2385–2390.
   PubMed Web of Science ®Google Scholar
• PEDERSEN O, BAGGER H, KELLER N, MARCHANT B, KOBER L, TORP-PEDERSEN C: Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function. Circulation (2001) 104:292–296.
   PubMed Web of Science ®Google Scholar
• KOBER L, BLOCH THOMSEN P, MOLLER M et al.: Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial. Lancet (2000) 356:2052–2058.
   PubMed Web of Science ®Google Scholar
• TORP-PEDERSEN C, MOLLER M, BLOCH-THOMSEN P: Dofetilide in patients with congestive heart failure and left ventricular dysfitction. N EngL J. Med. (1999) 341:857–865.
   PubMed Web of Science ®Google Scholar
• NORGAARD B, WACHTELL K, CHRISTENSEN P et al.: Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation. Am. Heart J. (1999) 137:1062–1069.
   PubMed Web of Science ®Google Scholar
• SUNG R, TAN H, KARAGOUNIS L et al.: Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled sudy. Am. Heart J. (1995) 129(4):739–748.
   PubMed Web of Science ®Google Scholar
• PLEWAN A, LEHMANN G, NDREPEPA G et al.: Maintenance of sinus rhythm after electrical cardioversion of persistent atrial fibrillation. Eur. Heart J. (2001) 22:1504–1510.
   PubMed Web of Science ®Google Scholar
• ROBERTS S, DIAZ C, NOLAN P et al: Effectiveness and costs of digoxin treatment for atrial fibrillation and flutter. Am. J. CardioL (1993) 72:567–573.
   PubMed Web of Science ®Google Scholar
• FARSHI R, KISTNER D, SARMA J, LONGMATE J, SINGH B: Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open label study of five drug regimens. J. Am. Coll. Cardiol. (1999) 33:304–310.
   PubMed Web of Science ®Google Scholar
• MURGATROYD F, GIBSON S, BAIYAN X et al.: Double-blind placebo-controlled trial of digoxin in symptomatic paroxysmal atrial fibrillation. Circulation (1999) 99(21):2765–2770.
   PubMed Web of Science ®Google Scholar
• GALUN E, FLUGELMAN M, GLICKSON M, ELIAKIM M: Failure of long-term digitalisation to prevent rapid ventricular response in patients with paroxysmal atrial fibrillation. Chest (1991) 99:1038–1040.
   PubMed Web of Science ®Google Scholar
• RINKENBERGER R, PRYSTOWSKI E, HEGER J, TROUP P, JACKMANN W, ZIPES D: Effects of intravenous and chronic oral verapamil administration in patients with supraventricular tachyarrhythmias. Circulation (1980) 62:996–1010.
   PubMed Web of Science ®Google Scholar
• ELLENBOGEN K, DIAS V, CARDELLO F et al.: Safety and efficacy of intravenous diltiazem in atrial fibrillation or atrial flutter. Am. J. CardioL (1995) 75:45–49.
   PubMed Web of Science ®Google Scholar
• BALSER J, MARTINEZ E, WINTERS B et al.: Beta-adrenergic blockade accelerates conversion of postoperative supraventricular tachyarrhythmias. Anesthesiology (1998) 89:1052–1059.
   PubMed Web of Science ®Google Scholar
• COX J, TM S: The surgical management ofatrial fibrillation. Ann. Rev. Med. (1997) 48:511–523.
   PubMed Web of Science ®Google Scholar
• COX J, JAQUISS R, SCHUESSLER R, BOINEAU J: Modification of the maze procedure for atrial flutter and atrial fibrillation. II. Surgical technique of the maze III procedure. J. Thorac. Cardiovasc. Surg (1995) 110:485–495.
   PubMed Web of Science ®Google Scholar
• COX J: The surgical treatment of atrial fibrillation. IV Surgical technique. Thorac. Cardiovasc. Surg (1991) 101:584–592.
   Web of Science ®Google Scholar
• MELO J, SANTIAGO T, GOUVEIA R, MARTINS k Atrial ablation for the surgical treatment of atrial fibrillation: principles and limitations. J. Card. Surg (2004) 19:207–210.
   PubMed Web of Science ®Google Scholar
• AD N, COX J: The Maze procedure for thetreatment of atrial fibrillation: a minimally invasive approach. J. Card. Surg. (2004) 19:196–200.
   PubMed Web of Science ®Google Scholar
• MAGNANO A, WOOLLETT I, GARAN H: Percutaneous catheter ablation procedures for the treatment of atrial fibrillation. J. Card. Surg. (2004) 19:188–195.
   PubMed Web of Science ®Google Scholar
• PAPPONE C, ROSANIO S: Evolution of non-pharmacological curative therapy for atrial fibrillation: where do we stand today? Int. J. Cardiol. (2002) 88:135–142.
   Web of Science ®Google Scholar
• WIESFELD A, TAN E, VAN VELDHUISEN D, CRIJNS H, VAN GELDER I: Radiofrequency of atrial fibrillation. Int. J. CardioL (2004) 93(2-3):231–237.
   PubMed Web of Science ®Google Scholar
• MITCHELL A, SULKE N: Does rapid atrial pacing terminate atrial fibrillation? A comparison of laboratory and device termination studies. Card. ElectrophysioL Rev. (2003) 7:352–354.
   PubMedGoogle Scholar
• GOLD M, SULKE N, SCHWARTZMAN D, MEHRA R, EULER D: Clinical experience with a dual-chamber implantable cardioverter defibrillator to treat atrial tachyarrhythmias. Cardiovasc. ElectrophysioL (2001) 12:1247–1253.
   PubMed Web of Science ®Google Scholar
• NEWMAN D, DORIAN P, PAQUETTE M: Effect of an implantable cardioverter defibrillator with atrial detection and shock therapies on patient-perceived, health-related quality of life. Am. Heart J. (2003) 145:841–846.
   PubMed Web of Science ®Google Scholar
• BURNS J, SEARS S, SOTILE R et al.: Do patients accept implantable atrial defibrillation therapy? Results from the Patient Atrial Shock Survey of Acceptance and Tolerance (PASSAT) Study. J. Cardiovasc. ElectrophysioL (2004) 15:286–291.
   PubMed Web of Science ®Google Scholar
• KAY G, BUBIEN R, EPSTEIN A, PLUMB V: Effect of catheter ablation of the atrioventricular junction on quality of life and exercise tolerance in paroxysmal atrial fibrillation. Am. J. Cardiology (1988) 62:741–744.
   PubMed Web of Science ®Google Scholar
• HOHNLOSER S, DORIAN P, STRAUB M, BECKMANN K, KOWEY P: Safety and efficacy of intravenously administered tedisamil for rapid conversion of recent-onset atrial fibrillation or atrial flutter. J. Am. Coll. CardioL (2004) 44(1):99–104.
   PubMed Web of Science ®Google Scholar
• NATTEL S, YUE L, WANG Z: Cardiac ultrarapid delayed rectifiers. Cell Physiol. Biochem. (1999) 9:217–226.
   PubMed Web of Science ®Google Scholar
• LI G, FENG J, WANG Z, FERMINI B, NATTEL S: Adrenergic modulation of ultrarapid delayed rectifirer K sup plus current in human atrial myocytes. Circ. Res. (1996) 78(5):903–915.
   PubMed Web of Science ®Google Scholar
• NAGASAWA H, FUJIKI A. FUJIKURA N,MATSUDA T, YAIVIASHITA T, INOUE H: Effects of a novel class III antiarrhythmic agent, NIP-142, on canine atrial fibrillation and flutter. Circ. J. (2002) 66(2):185-191.70. WIRTH K, PAEHLER T, ROSENSTEIN B et al.: Atrial effects of the novel K+-channel-blocker AVE0118 in anesthetized pigs. Cardiovasc. Res. (2003) 60:298–306.
   PubMed Web of Science ®Google Scholar
• HEIDBUCHEL H: A paradigm shift in treatment for atrial fibrillation: from electrical to structural therapy? Eur. Heart J. (2003) 24:2077–2078.
   Google Scholar
• FRUSTACI A, CHIMENTI C, PIERONI M: Idiopathic myocardial vasculitis presenting as restrictive cardiomyopathy. Circulation (1997) 111:1462–1464.
   Google Scholar
• DERNELLIS J, PANARETOU M: Relationship between C-reactive protein concentrations during glucocorticoid therapy and recurrent atrial fibrillation. Eur. Heart J. (2004) 25:1100–1107.
   PubMed Web of Science ®Google Scholar
• FISCHBACH P, BARRETT T, GOYAL R et al.: Conversion of atrial fibrillation by the experimental drug tedisamil in two canine models. J. Cardiovasc. ElectrophysioL (2001) 12(10):1138–1144.
   PubMed Web of Science ®Google Scholar
• VAN OPSTAL J, SCHOENMAKERS M, VERDUYN S et al.: Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome. Circulation (2001) 104:2722–2727.
   PubMed Web of Science ®Google Scholar
• BAIÁTI B, IOST N, SIMON J, VARRO A, PAPP J: Analysis of the electrophysiological effects of ambasilide, a new antiarrhythmic agen in canine isolated ventricular muscle and Purkinje fibers. Gen. Pharm. (2000) 34:85–93.
   PubMedGoogle Scholar
• CONNOLLY SJ, SCHNELL DJ, PAGE RL, WILKINSON WE, MARCELLO SR, PRITCHETT EL: Dose-response relations of azimilide in the management of symptomatic, recurrent, atrial fibrillation. Am. J. CardioL (2001) 88:974–979.
   PubMed Web of Science ®Google Scholar
• WANG J, FENG J, NATTEL S: Class IIIantiarrhythmic drug action in experimental atrial fibrillation: differences in reverse use dependence and effectivensess between D-sotalol and the new antiarrhythmic drug ambasilide. Circulation (1994) 90(4):2032–2040.
   PubMed Web of Science ®Google Scholar
• PRITCHETT E, PAGER, CONNOLLY S, MARCELLO S, SCHNELL D, -WILKINSON W: Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-response. J. Am. Coll. CardioL (2000) 36:794–802.
   PubMed Web of Science ®Google Scholar
• PRATT C, SINGH S, AL-KHALIDI H et al.: The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction. J. Am. Coll. CardioL (2004) 43:1211–1216.
   PubMed Web of Science ®Google Scholar
• KNOBLOCH K, BRENDEL J, PEUKERT S: Electrophysiological and antiarrhythmic effects of the novel IKur channel blockers, S9947 and S20951, on left versus right pig atrium in vivo in comparison with the IKr blockers dofetilide, azimilide, D,L-sotalol and Ibutilide. Naunyn-Schmiedeberg's Arch. PharmacoL (2002) 366:482–487.
   Google Scholar
• RAHME M, COTTER B, LEISTAD E et al.: Electrophysiological and antiarrhythmic effects of the atrial selective 5-HT4 receptor antagonist RS-100302 in experimental atrial flutter and fibrillation. Circulation (1999) 100(19):2010–2017.
   PubMed Web of Science ®Google Scholar
• PEDERSEN O, BAGGER H, KOBER L, TORP-PEDERSEN C: Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation (1999) 100(4):376–380.
   PubMed Web of Science ®Google Scholar
• GOETTE A, STAACK T, ROCKEN C et al.: Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J. Am. Coll. CardioL (2000) 35:1669–1677.
   PubMed Web of Science ®Google Scholar
• NAKASHIMA H, KUMAGAI K, HIDENORI U, GONDO N, IDEISHI M, ARAKAWA K: Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation (2000) 101(22):2612–2617.
   PubMed Web of Science ®Google Scholar
• BOTTO G, LUZI M, SAGONE A: Atrialfibrillation: the remodelling phenomenon. Eur. Heart]. (2003) 5(Suppl. H):H1–H7.
   Google Scholar
• DE SIMONE A, DE PASQUALE M, DE MATTEIS C et al.: Verapamil plus antiarrhythmic drugs reduce atrial fibrillation recurrences after an electrical cardioversion (VEPARAF Study). Eur. Heart]. (2003) 24:1425–1429.
   PubMed Web of Science ®Google Scholar
• KINEBUCHI O, MITAMURA H, SHIROSHITA-TAKESHITA A et al: Oral verapamil attenuates the progression of pacing-induced electrical and mechanical remodeling of the atrium. Circ. J. (2004) 68(5):494–500.
   PubMed Web of Science ®Google Scholar
• GERSTENFELD E, GUERRA P, SPARKS P, HATTORI K, LESH M: Clinical outcome after radiofrequency catheter ablation of focal atrial fibrillation triggers. Cardiovasc. ElectrophysioL (2001) 12:900–908.
   PubMed Web of Science ®Google Scholar
• FRIEDMAN P, DIJKMAN B, WARMAN E et al.: Atrial theraies reduce atrial arrhythmia burden in defibrillatior patients. Circulation (2001) 104:1023–1028.
   PubMed Web of Science ®Google Scholar
• KROL R, SAKSENA S, PRAKASH A: New devices and hybrid therapies for treatment of atrial fibrillation. J. Interv. Card. ElectrophysioL (2000) 4(Suppl. 1):163–169.
   PubMed Web of Science ®Google Scholar
• SAKSENA S, MADAN N: Hybrid therapy of atrial fibrillation: algorithms and outcome. J. Interv. Card ElectrophysioL (2003) 9:235–247.
   PubMed Web of Science ®Google Scholar
• YOSHIDA T, NIWANO S, INUO K et al.: Bepridil prevents paroxysmal atrial fibrillation by a class III antiarrhythmic drug effect. Pace (2003) 26:314–317.
   Google Scholar
• PEDERSEN O, KOBER L, TORP-PEDERSEN C: Atrial fibrillation and atrial cardiomyopathy — two sides of the same coin? Am. Heart]. (2004) 147:953–955.
   PubMed Web of Science ®Google Scholar